Comparative analysis of the therapeutic effect of antibiotic bone cement on Wagner grade 3 or 4 diabetic foot ulcer in heel and non-heel areas: a retrospective cohort study
Jian Y., Li L., Chen W., An W., Guan R., Zhang Y.
Retrospective Study with a reported sample of 35 on Diabetic Foot, Chronic Wound, published in Front Endocrinol (Lausanne) (2025) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Retrospective Study
- Journal
- Front Endocrinol (Lausanne) (2025)
- Reported sample size
- 35
- Source database
- Europe PMC
- PMID
- 41384024
- PMCID
- PMC12689374
- DOI
- 10.3389/fendo.2025.1662731
Abstract (original English)
Background Heel diabetic foot ulcers (hDFU) represent a particularly severe form of DFU, characterized by prolonged healing times and a significantly elevated risk of major amputation. Effective strategies to control infection and improve outcomes in this high-risk population are urgently needed. While antibiotic bone cement (ABC) has emerged as a promising therapy for general DFU, its specific efficacy for hDFU remains unverified. This study aims to evaluate the clinical efficacy of ABC-based management for hDFU compared to non-heel DFU (nhDFU) and to identify risk factors for major amputation. Methods We conducted a retrospective cohort study of 77 patients with severe (Wagner grade 3 or 4) DFUs treated with an ABC protocol. Patients were stratified into hDFU (n=35) and nhDFU (n=42) groups. Propensity score matching (PSM) was used to balance baseline characteristics. Outcomes included major amputation rates, length of stay (LOS), infection control [measured by white blood cell (WBC) count], and risk factors analyzed via modified Poisson regression. Results At baseline, the hDFU group presented with greater disease severity, evidenced by significantly lower albumin levels (29.56 ± 6.45 g/L vs. 32.49 ± 5.25 g/L, P = 0.03) and higher WBC counts (Median: 14.86 vs. 10.32 × 10 9 /L, P = 0.002). After PSM, the major amputation rate was not significantly different between the hDFU an
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • Without an adequate control group, treatment effects cannot be separated from other factors.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level AMeta-analysisPubMed
Efficacy of Stem Cell-Derived Exosomes in Promoting Diabetic Foot Ulcer Healing: A Meta-Analysis of Preclinical Animal Studies.
Meta-analysis on Diabetic Foot, Chronic Wound, published in J Diabetes Res (2026) — summary generated from the PubMed abstract.
- 2026
J Diabetes Res - Level AMeta-analysisEurope PMC
Bone marrow-derived mesenchymal stem cells combined with intramuscular injection promote the healing of diabetic foot ulcers: a systematic review and meta-analysis
Meta-analysis with a reported sample of 2059 on Diabetic Foot, Chronic Wound, published in Front Endocrinol (Lausanne) (2026) — summary generated from the PubMed abstract.
- 2026
- n = 2059
Front Endocrinol (Lausanne) - Level AMeta-analysisEurope PMC
Comparative efficacy of advanced therapeutic modalities for diabetic foot ulcers: a systematic review and meta-analysis including NPWT, stem cells, ESWT, and bioengineered treatments
Meta-analysis on Diabetic Foot, published in Front Bioeng Biotechnol (2026) — summary generated from the PubMed abstract.
- 2026
Front Bioeng Biotechnol - Level AMeta-analysisPubMed
Therapeutic potential of adipose-derived stem cells for diabetic foot ulcers: a systematic review and meta-analysis.
Meta-analysis on Diabetic Foot, Chronic Wound, published in Diabetol Metab Syndr (2025) — summary generated from the PubMed abstract.
- 2025
Diabetol Metab Syndr6 citations - Level AMeta-analysisPubMed
A meta-analysis on application and prospect of cell therapy in the treatment of diabetes mellitus.
Meta-analysis on Diabetic Foot, Autoimmune Research, published in Stem Cell Res Ther (2025) — summary generated from the PubMed abstract.
- 2025
Stem Cell Res Ther - Level AMeta-analysisEurope PMC
Comparison of the efficacy of 12 interventions in the treatment of diabetic foot ulcers: a network meta-analysis
Meta-analysis with a reported sample of 356 on Diabetic Foot, Chronic Wound, published in PeerJ (2025) — summary generated from the PubMed abstract.
- 2025
- n = 356
PeerJ1 citations